Boris Gershman1, Paul Maroni2, Jon C Tilburt3, Robert J Volk4, Badrinath Konety5, Charles L Bennett6, Alexander Kutikov7, Marc C Smaldone7, Victor Chen8, Simon P Kim9,10. 1. Department of Urology, Brown University, Providence, RI, USA. 2. Division of Urology, University of Colorado, Denver, CO, USA. 3. Biomedical Ethics Research Program, Division of General Internal Medicine, Department of Medicine and the Division of Health Care Policy and Research, Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA. 4. Division of Cancer Prevention and Population Sciences, Department of Health Services Research, MD Anderson Cancer Center, University of Texas, Houston, TX, USA. 5. Department of Urology, University of Minnesota, Minneapolis, MN, USA. 6. College of Pharmacy, University of South Carolina, Columbia, SC, USA. 7. Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA. 8. Department of Urology , Loyola University Medical Center , Maywood, IL, USA. 9. Division of Urology, University of Colorado, Denver, CO, USA. simon.kim@ucdenver.edu. 10. Division of Urology, University of Colorado Anschutz Medical Center, University of Colorado School of Medicine, 12631 E. 17th Avenue, M/S 319, Aurora, CO, 80045, USA. simon.kim@ucdenver.edu.
Abstract
PURPOSE: Although prediction tools for prostate cancer (PCa) are essential for high-quality treatment decision-making, little is known about the degree of confidence in existing tools and whether they are used in clinical practice from radiation oncologists (RO) and urologists (URO). Herein, we performed a national survey of specialists about perceived attitudes and use of prediction tools. METHODS: In 2017, we invited 940 URO and 911 RO in a national survey to query their confidence in and use of the D'Amico criteria, Kattan Nomogram, and CAPRA score. The statistical analysis involved bivariate association and multivariable logistic regression analyses to identify physician characteristics (age, gender, race, practice affiliation, specialty, access to robotic surgery, ownership of linear accelerator and number of prostate cancer per week) associated with survey responses and use of active surveillance (AS) for low-risk PCa. RESULTS: Overall, 691 (37.3%) specialists completed the surveys. Two-thirds (range 65.6-68.4%) of respondents reported being "somewhat confident", but only a fifth selected "very confident" for each prediction tool (18.0-20.1%). 19.1% of specialists in the survey reported not using any prediction tools in clinical practice, which was higher amongst URO than RO (23.9 vs. 13.4%; p < 0.001). Respondents who reported not using prediction tools were also associated with low utilization of AS in their low-risk PCa patients (adjusted OR 2.47; p = 0.01). CONCLUSIONS: While a majority of RO and URO view existing prediction tools for localized PCa with some degree of confidence, a fifth of specialists reported not using any such tools in clinical practice. Lack of using such tools was associated with low utilization of AS for low-risk PCa.
PURPOSE: Although prediction tools for prostate cancer (PCa) are essential for high-quality treatment decision-making, little is known about the degree of confidence in existing tools and whether they are used in clinical practice from radiation oncologists (RO) and urologists (URO). Herein, we performed a national survey of specialists about perceived attitudes and use of prediction tools. METHODS: In 2017, we invited 940 URO and 911 RO in a national survey to query their confidence in and use of the D'Amico criteria, Kattan Nomogram, and CAPRA score. The statistical analysis involved bivariate association and multivariable logistic regression analyses to identify physician characteristics (age, gender, race, practice affiliation, specialty, access to robotic surgery, ownership of linear accelerator and number of prostate cancer per week) associated with survey responses and use of active surveillance (AS) for low-risk PCa. RESULTS: Overall, 691 (37.3%) specialists completed the surveys. Two-thirds (range 65.6-68.4%) of respondents reported being "somewhat confident", but only a fifth selected "very confident" for each prediction tool (18.0-20.1%). 19.1% of specialists in the survey reported not using any prediction tools in clinical practice, which was higher amongst URO than RO (23.9 vs. 13.4%; p < 0.001). Respondents who reported not using prediction tools were also associated with low utilization of AS in their low-risk PCa patients (adjusted OR 2.47; p = 0.01). CONCLUSIONS: While a majority of RO and URO view existing prediction tools for localized PCa with some degree of confidence, a fifth of specialists reported not using any such tools in clinical practice. Lack of using such tools was associated with low utilization of AS for low-risk PCa.
Entities:
Keywords:
Active surveillance; Decision aids; National survey; Prostate cancer; Shared decision-making
Authors: Timothy J Wilt; Karen M Jones; Michael J Barry; Gerald L Andriole; Daniel Culkin; Thomas Wheeler; William J Aronson; Michael K Brawer Journal: N Engl J Med Date: 2017-07-13 Impact factor: 91.245
Authors: Michael W Kattan; Michael J Zelefsky; Patrick A Kupelian; Daniel Cho; Peter T Scardino; Zvi Fuks; Steven A Leibel Journal: J Clin Oncol Date: 2003-12-15 Impact factor: 44.544
Authors: Benjamin D Sommers; Clair J Beard; Anthony V D'Amico; Irving Kaplan; Jerome P Richie; Richard J Zeckhauser Journal: Cancer Date: 2008-10-15 Impact factor: 6.860
Authors: Andrew J Stephenson; Michael W Kattan; James A Eastham; Fernando J Bianco; Ofer Yossepowitch; Andrew J Vickers; Eric A Klein; David P Wood; Peter T Scardino Journal: J Clin Oncol Date: 2009-07-27 Impact factor: 44.544
Authors: Simon P Kim; Jon C Tilburt; R Jeffrey Karnes; Jeanette Y Ziegenfuss; Leona C Han; Nilay D Shah; Igor Frank; Marc C Smaldone; Cary P Gross; James B Yu; Quoc-Dien Trinh; Maxine Sun; Rebecca L O'Malley; Paul L Nguyen Journal: Urology Date: 2013-08-01 Impact factor: 2.649
Authors: A V D'Amico; R Whittington; S B Malkowicz; D Schultz; K Blank; G A Broderick; J E Tomaszewski; A A Renshaw; I Kaplan; C J Beard; A Wein Journal: JAMA Date: 1998-09-16 Impact factor: 56.272
Authors: Kayla Collado; Sarah L Kerns; Michael A Diefenbach; Elizabeth Peterson-Roth; Raymond Koski; Harry Ostrer; Richard G Stock; Martin Mattessich; Paul Kaplan; Barry S Rosenstein Journal: Adv Radiat Oncol Date: 2020-04-18
Authors: Mieke Van Hemelrijck; Xinge Ji; Jozien Helleman; Monique J Roobol; Daan Nieboer; Chris Bangma; Mark Frydenberg; Antti Rannikko; Lui Shiong Lee; Vincent Gnanapragasam; Michael W Kattan Journal: Transl Androl Urol Date: 2021-03